177 related articles for article (PubMed ID: 37903476)
1. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
Al-Sawaf O
Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
3. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Stumpf J; Al-Sawaf O
Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
6. MRD-directed therapy in CLL: ready for prime time?
Rhodes JM; Lopez CA; Barrientos JC
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):413-420. PubMed ID: 38066928
[TBL] [Abstract][Full Text] [Related]
7. The role of minimal residual disease in chronic lymphocytic leukemia.
Al-Sawaf O; Hallek M; Fischer K
Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
9. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
Heltai S; Ghia P; Scarfò L
Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
[TBL] [Abstract][Full Text] [Related]
10. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
11. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
12. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
13. Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Al-Sawaf O; Seymour JF; Kater AP; Fischer K
Hematol Oncol Clin North Am; 2021 Aug; 35(4):775-791. PubMed ID: 34102145
[TBL] [Abstract][Full Text] [Related]
14. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
[TBL] [Abstract][Full Text] [Related]
15. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Gauthier M; Comont T; Vergez F; Ysebaert L
Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
[TBL] [Abstract][Full Text] [Related]
16. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
17. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
18. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
20. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
